JP2018537093A - 異所性石灰化障害を治療するための組成物およびそれを使用する方法 - Google Patents

異所性石灰化障害を治療するための組成物およびそれを使用する方法 Download PDF

Info

Publication number
JP2018537093A
JP2018537093A JP2018526182A JP2018526182A JP2018537093A JP 2018537093 A JP2018537093 A JP 2018537093A JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018537093 A JP2018537093 A JP 2018537093A
Authority
JP
Japan
Prior art keywords
polypeptide
domain
amino acid
amino acids
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537093A5 (enExample
Inventor
デメトリオス ブラッドドック
デメトリオス ブラッドドック
ラ クルーズ エンリケ デ
ラ クルーズ エンリケ デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2018537093A publication Critical patent/JP2018537093A/ja
Publication of JP2018537093A5 publication Critical patent/JP2018537093A5/ja
Priority to JP2021208914A priority Critical patent/JP2022046619A/ja
Priority to JP2024014533A priority patent/JP2024032952A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03036—Phosphoinositide 5-phosphatase (3.1.3.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
JP2018526182A 2015-11-20 2016-11-21 異所性石灰化障害を治療するための組成物およびそれを使用する方法 Pending JP2018537093A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021208914A JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257883P 2015-11-20 2015-11-20
US62/257,883 2015-11-20
PCT/US2016/063034 WO2017087936A1 (en) 2015-11-20 2016-11-21 Compositions for treating ectopic calcification disorders, and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021208914A Division JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2018537093A true JP2018537093A (ja) 2018-12-20
JP2018537093A5 JP2018537093A5 (enExample) 2020-01-09

Family

ID=58719303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018526182A Pending JP2018537093A (ja) 2015-11-20 2016-11-21 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2021208914A Pending JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A Pending JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021208914A Pending JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A Pending JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Country Status (6)

Country Link
US (3) US20180371434A1 (enExample)
EP (2) EP4079322A1 (enExample)
JP (3) JP2018537093A (enExample)
AU (2) AU2016355715A1 (enExample)
CA (1) CA3005142A1 (enExample)
WO (1) WO2017087936A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046619A (ja) * 2015-11-20 2022-03-23 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100803A2 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
EP3493829B1 (en) 2016-08-05 2024-04-17 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
AU2019327572B2 (en) 2018-08-31 2025-11-13 Yale University ENPP1 polypeptides and methods of using same
TW202216186A (zh) * 2020-07-02 2022-05-01 美商伊諾臻醫藥公司 用於治療同種異體移植物血管病變之組成物與方法
AU2021356692A1 (en) * 2020-10-08 2023-05-04 Biomarin Pharmaceutical Inc. Liver specific production of enpp1 or enpp3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008188015A (ja) * 2001-11-07 2008-08-21 Agensys Inc 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH07507059A (ja) 1992-03-25 1995-08-03 デポムド　システムズ，インコーポレイテッド アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP0739488A1 (en) 1994-01-14 1996-10-30 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
CA2610159C (en) 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
DK2046373T3 (da) 2006-08-02 2013-05-27 Althea Technologies Inc Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse
US20080273206A1 (en) * 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
AU2011362576B2 (en) 2011-03-11 2017-06-08 Alexion Pharmaceuticals, Inc. NPP1 fusion proteins
PL2956163T3 (pl) 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
WO2016100803A2 (en) 2014-12-19 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
MX391074B (es) 2015-05-19 2025-03-21 Univ Yale Composiciones para el tratamiento de condiciones patológicas de calcificación y sus métodos de uso.
CA3005142A1 (en) * 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008188015A (ja) * 2001-11-07 2008-08-21 Agensys Inc 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Accessin No. O14638", DATABASE UNIPROT, JPN6020041226, 7 January 2015 (2015-01-07), ISSN: 0004377841 *
THE JOURNAL OF RHEUMATOLOGY, vol. 28:12, JPN6020041227, 2001, pages 2681 - 2691, ISSN: 0004576165 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046619A (ja) * 2015-11-20 2022-03-23 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
US12234489B2 (en) 2015-11-20 2025-02-25 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Also Published As

Publication number Publication date
US12234489B2 (en) 2025-02-25
US20230227800A1 (en) 2023-07-20
EP4079322A1 (en) 2022-10-26
US20180371434A1 (en) 2018-12-27
AU2016355715A1 (en) 2018-05-31
EP3377105A4 (en) 2019-04-24
CA3005142A1 (en) 2017-05-26
WO2017087936A1 (en) 2017-05-26
JP2024032952A (ja) 2024-03-12
EP3377105A1 (en) 2018-09-26
JP2022046619A (ja) 2022-03-23
US20210032610A1 (en) 2021-02-04
AU2023226739A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
JP2018537093A (ja) 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP7778392B2 (ja) 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
JP2007533669A (ja) 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
CN107320719A (zh) Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途
JP2018500315A (ja) 組織石灰化の治療方法
JP2023011938A (ja) ファーバー病を治療するための組成物及び方法
JP7299632B2 (ja) 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化
AU2019215009B2 (en) Methods and compositions for inhibiting ADAM 9 biological activities
EP1124572B1 (en) Genes and proteins predictive and therapeutic for renal disease and associated disorders
JP5737721B2 (ja) Ｈｔｒａ１変異と家族性虚血性脳小血管病との関連
US20250388882A1 (en) Compositions for treating ectopic calcification disorders, and methods using same
HK40082720A (en) Compositions for treating ectopic calcification disorders, and methods using same
US9452195B2 (en) Use of CHEC peptides to treat neurological and cardiovascular diseases and disorders
TW200307132A (en) Diagnosis and treatment of glaucoma and methods for discovering new glaucoma therapeutic agents based on the Wnt/Ca2+ signaling pathway
BR122025001586A2 (pt) Composto compreendendo um polipeptídeo solúvel de ectonucleotídeo pirofosfato/fosfodiesterase-1 (enpp1), e seu uso
BR112017024141B1 (pt) Composto compreendendo um polipeptídeo solúvel de ectonucleotídeo pirofosfato/fosfodiesterase-1 (enpp1), e seu uso

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210825